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ABSTRACT
The utility of the levels of amyloid beta (Ab)
peptide and tau in blood for diagnosis, drug
development, and assessment of clinical trials
for Alzheimer’s disease (AD) has not been
established. The lack of availability of
ultra-sensitive assays is one critical issue that
has impeded progress. The levels of Ab species
and tau in plasma and serum are much lower
than levels in cerebrospinal fluid. Furthermore,
plasma or serum contain high levels of
assay-interfering factors, resulting in difficulties
in the commonly used singulex or multiplex
ELISA platforms. In this review, we focus on two
modern immune-complex-based technologies
that show promise to advance this field. These
innovative technologies are immunomagnetic
reduction technology and single molecule array
technology. We describe the technologies and
discuss the published studies using these tech-
nologies. Currently, the potential of utilizing
these technologies to advance Ab and tau as
blood-based biomarkers for AD requires further
validation using already collected large sets of
samples, as well as new cohorts and popula-
tion-based longitudinal studies.
Keywords: Alzheimer’s disease; Amyloid beta;
Blood biomarkers; Plasma; Tau; Ultra-sensitive
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INTRODUCTION
Alzheimer’s disease (AD) core pathological
components, amyloid beta (Ab) peptide 42
(Ab42), Ab40, tau, and tau phosphorylated at
threonine-181 (Thr181P), have been targets for
biomarker development for two decades [1–5].
The underlying rationale of using these mole-
cules as biomarkers of AD is that definitive
diagnosis of this condition relies on confirma-
tion from neuropathological hallmarks con-
taining these components, and the ability of
tracking or measuring these components in
brains or biofluids of living subjects could pro-
vide evidence of ongoing pathophysiology.
There has been tremendous progress made
towards achieving this goal. Ligands have been
developed for visualizing amyloid or tau
pathologies in the brain by positron emission
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tomography (PET) [6, 7]. The utility of amyloid
imaging and cerebrospinal fluid (CSF)
biomarkers of Ab and tau for clinical diagnosis
has been validated in large cohorts and popu-
lation studies, as well as in neuropathologically
confirmed cases [8–15]. The use of the ratios of
CSF Ab42 to tau or Thr181P has been estab-
lished as a means for identifying clinically
diagnosed AD [2, 9, 16–22]. The inclusion of AD
core biomarkers in the criteria for the diagnosis
of probable and possible AD has been recom-
mended by the National Institute on
Aging–Alzheimer’s Association workgroups
[23–26]. The strategy of combining amyloid
visualization by PET and CSF core markers has
been demonstrated to improve the accuracy of
predicting the pre-clinical stage of AD [25, 26].
As PET primarily visualizes fibrillar amyloid
deposits, CSF Ab measures could be more sen-
sitive in detecting changes in Ab levels at the
pre-clinical stage or even earlier [27–29]. By
contrast, the development of assays for use in
measuring AD core pathological molecules in
blood as disease biomarkers has fallen behind
[30, 31]. Several factors could have hampered
the development. One of the major challenges
in developing AD core pathological compo-
nents such as blood biomarkers has been the
lack of sensitive assays. Analyses using singulex
or multiplex enzyme-linked immunosorbent
assay (ELISA) platforms for determining the
levels of Ab and tau in plasma or serum have led
to conflicting findings—with levels either
unchanged, decreased, or increased from the
normal controls—suggesting limitations due to
the assay platforms [32–41].
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
FACTORS AFFECTING ASSAY
RESULTS OF BLOOD AD CORE
BIOMARKERS
The discrepancy in the levels of AD core markers
in blood samples could be due to a wide range
of causes: biological nature, assay sensitivity,
platform, sample processing, storage condition,
clinical criteria, and/or demographic features of
the participants, as discussed in a previous
review [42]. From a biological point of view, the
concentrations of Ab and tau in the circulation
are much lower than those in the CSF because
these molecules present in the brain do not
directly enter the circulation due to the pres-
ence of the blood–brain barrier (BBB). Some Ab
molecules are cleared at the BBB through
receptor-mediated mechanisms, but others are
cleared from the CSF through the lymphatic
drainage system [43–45].
The assay platforms for measuring CSF Ab,
tau, and Thr181P, namely traditional singulex
ELISA and luminex-based multiplex ELISA, are
well-established [19, 46–48]. It has been con-
sistently shown that compared to normal con-
trols Ab42 levels in the CSF are lower in patients
with AD, while both tau and phosphorylated
tau (p-tau) levels are higher in patients with AD
(for example, see [48]). Combining CSF tau,
p-tau, or Ab40 levels as ratios with Ab42 is more
effective than standalone markers in predicting
brain Ab deposition detected by PET imaging in
patients with AD or in the preclinical stage of
AD [49–51].
Figueski et al. measured Ab42 and Ab40
levels in plasma samples using similar ELISA
platforms and found that the plasma levels were
one-fifth to one-tenth the levels found in the
CSF [33]. Using an ultra-sensitivity platform,
Janelidze et al. found even wider differences in
detection levels between plasma and CSF sam-
ples [36]. Plasma Ab levels tend to be near the
lower limits of detection of current ELISA assays
and close to the low-end of the linear range of a
calibration curve. Under these conditions, the
ELISA assays lose their sensitivity for detecting
narrow differences between biological samples.
The performance of immunoassays also
depends on the epitopes and affinity of the
antibodies selected for capturing antigen con-
tained in the samples. Moreover, plasma and
serum contain high concentrations of albumin
and immunoglobulins, which are known
Ab-binding proteins that can interfere with
accurate detection of the free forms of Ab
[52, 53]. Endogenous immunoglobulins,
autoantibodies, and heterophilic antibodies can
also interfere with the performance of ELISAs.
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This has been discussed in depth previously
[54].
In addition to the above-mentioned factors,
improper sample handling can affect assay
accuracy. Most of the lessons in this regard were
learned during the process of establishing these
AD core markers for CSF. As plasma contains
much higher concentrations of proteins,
including degradative enzymes, as well as more
complex components than CSF, additional
problems of these sorts are to be expected.
These include the need for rigorous procedures
of sample collection, volume of sample ali-
quots, type of tubes for storing aliquots, number
of freeze–thaw cycles, type of calibration pro-
teins, batch-to-batch reagent variability, and
site-to-site operations [55].
ULTRA-SENSITIVE TECHNOLOGIES
To overcome the challenges of detection
encountered using traditional ELISA platforms,
new approaches and technologies are emerging
with the potential to provide superior sensitiv-
ity and specificity for measuring Ab and tau in
blood samples [56–58]. For example, a new
approach that used immunoprecipitation to
pull down various Ab fragments in plasma
samples followed by mass-spectrophotometry
analysis has led to discovery of a new marker,
APP669–711, whose ratio to Ab1-42 demon-
strated 93% sensitivity and 96% specificity to
discriminate Pittsburgh compound B (PIB)-pos-
itive subjects from PIB-negative subjects [58].
New immunoaffinity-based assays have also
been applied to AD core marker analysis in
biofluids, including immunomagnetic reduc-
tion (IMR) and single molecule array (SIMOA)
for the analysis of plasma samples and the assay
by Meso Scale Discovery (Rockville, MD) for CSF
samples [59]. Here, we limit the scope of this
review to the IMR and SIMOA assays, which
have been used to quantify plasma Ab and tau
in studies involving medium to large numbers
of subjects.
The IMR technology was developed by
MagQu Company, Ltd. (New Taipei City, Tai-
wan), and the SIMOA technology was devel-
oped by Quanterix (Lexington, MA).
Quantification with both platforms is based on
immunoreactivity between specific antibodies
and analytes or protein standards. However, the
principle and design of the two detection sys-
tems are quite different. IMR technology detects
alternating-current magnetic susceptibility by a
superconducting quantum interference device
(SQUID), while SIMOA technology detects the
presence of antigen by fluorescence imaging of
single enzyme-labeled immunocomplexes
reacting with the fluorogenic substrate, resor-
ufin b-D-galactopyranoside [57, 60]. The tech-
nical features of the two platforms are
summarized in Table 1.
IMR Technology
Immunomagnetic reduction assays quantify the
concentrations of analytes in a sample by mea-
suring the percentage magnetic signal reduction
after immunocomplex formation at the surface
of magnetic nanobeads, with the magnetic sig-
nals being detected by SQUID [57]. The binding
of antibody with analytes changes the oscilla-
tion speed of the magnetic nanoparticles under
a mixed frequency alternating current. Thus,
the magnitude of reduction in the oscillation
speed corresponds to the amount of the ana-
lytes bound to the antibodies. Sample analyte
concentration is calculated according to the
established relationship of protein standard
concentrations and associated percentage IMR
[57, 61].
The IMR reagents manufactured by MagQu
Company contain capture antibody-conjugated
magnetic nanobeads (diameter 50–60 nm) at a
concentration of 109 beads per milliliter. Cur-
rent IMR reagents use a monoclonal antibody to
tau that recognizes six isoforms: a rabbit poly-
clonal antibody to Ab37–42 for the Ab42 assay
and a mouse monoclonal antibody to the N--
terminal of Ab as Ab40 capture antibody.
Although it has been shown that spiking with
Ab42 did not increase the measured levels of
Ab40 in an IMR Ab40 assay, the possibility of
measuring both Ab species by the IMR Ab40
assay using the current antibody remains to be
clarified [57].
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Table 1 Summary of the immunomagnetic reduction and single molecule array technologies
Assay
characteristics
IMRa SIMOAa
Assay principles The IMR assay measures the change in magnetic
susceptibility over time caused by the
association of antigen with antibody-coated
paramagnetic nanobeads
Digital ELISA counts antibody coated paramagnetic
microbeads that have undergone a procedure
similar to conventional ELISA techniques
Diameter of
magnetic
beads
50–60 nm 2.7 lm
Capture
antibodies
Tau: Anti-tau (Sigma, St. Louis, MO; T9450)
Ab42: Anti-b amyloid 37–42 (ABCAM,
Cambridge, UK; ab34376)
Ab40: Anti-b amyloid (Sigma; A3981) [61]
Tau: Tau5 targeting a linear epitope in the
mid-region of all tau isoforms
Ab42/Ab40: Antibodies targeting N-terminus of
Ab
Detection
antibodies
None Tau: HT7 and BT2 targeting linear epitopes in the
N-terminal region of T-tau
Ab42/Ab40: biotinylated C-terminal-specific
antibodies
Washing steps None Two 3-step washes, and one 8-step wash with 59
phosphate buffered saline ? 0.1% Tween-20
Type of signals
for detection
Magnetic susceptibility detected by SQUID
magnetometer
Digital counting of enzyme-labeled and unlabeled
microbeads via presence and absence of fluorescent
substrate
Equipment
capacity
36 Wells (XacPro-S) 96-well plate (four 24-array discs)
(Simoa HD-1) [63]
Low limit of
detection
Tau: 0.002 pg/ml
Ab42: 7.53 pg/ml
Ab40: 4.91 pg/ml
Tau: 0.019 pg/ml
Ab42: 0.044 pg/ml
Ab40: 0.522 pg/ml
Low limit of
quantification
Information not available Tau: 0.061 pg/ml
Ab42: 0.137 pg/ml
Ab40: 1.23 pg/ml
Assay range Tau: 0.002–2500 pg/ml
Ab42: 7.53–50,000 pg/ml
Ab40: 4.91–500 pg/ml
Tau: 0–360 pg/ml
Ab42: 0–400 pg/ml
Ab40: 0–800 pg/ml
Sample volume
(plasma)
Tau: 40 ll
Ab42: 60 ll
Ab40: 40 ll
Tau: 45.5 ll
Ab42: 32.5 ll
Ab40: 32.5 ll
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The IMR procedure requires no washing
steps. The antibody-containing IMR reagent is
mixed with samples at a defined volume ratio.
Plasma samples are not pre-diluted, and the
total volume for each assay is 120 ll, with the
detection of reaction being measured over a 5-h
period. The company has developed a 36--
channel SQUID-based immunomagnetic ana-
lyzer (Model Xac-Pro-S). Additional information
for the IMR assays is listed in Table 1.
SIMOA Technology
The SIMOA assay detects the presence of anti-
gen at the single molecule level using digital
counting technology [60, 62]. An assay-specific
capture antibody is attached to 2.7-lm param-
agnetic microbeads that contain 250,000 anti-
body attachment sites per bead. The assay
procedure involves formation of antigen–anti-
body immune complexes at the surface of the
microbeads, followed by interaction with first a
biotinylated-detection antibody and then
streptavidin-beta galactosidase. The microbeads
are allowed to settle into individual femto-
liter-sized wells containing fluorogenic enzyme
substrate. Those wells containing fluorescent
signals generated by the beta-galactosidase
reaction with the substrate are detected and
counted by a fluorescence analyzer. The calcu-
lation of antigen concentration in the sample is
based on the ratio of the number of the wells
containing an enzyme-labeled bead to the total
number of wells containing a bead [measuring
unit is average enzymes per bead (AEB)]. The
Quanterix company has developed a high-ca-
pacity, fully automated SIMOA HD-1 Analyzer
that can handle triplex analysis (assays for
cytokines: tumor necrosis factor-alpha, inter-
leukin (IL)-6 and -10) [63]. The details of two--
plex and three-plex assays that analyze Ab and
tau levels are also available at the company’s
website (www.quanterix.com). The overall
instrument throughput is 68 samples/h at stea-
dy-state usage, while it takes 2 h to assay a 96--
well plate [63]. Additional information on
SIMOA assays is shown in Table 1.
MEASUREMENT OF AB AND TAU
IN HUMAN PLASMA USING SIMOA
AND IMR TECHNOLOGIES
The IMR and SIMOA assays were developed to
increase the detection sensitivity of
immunoassays, and they have been used to
analyze plasma levels of Ab and tau in human
subject studies.
Studies using IMR assays have mainly been
conducted in Taiwanese cohorts [57, 61, 64–66],
and studies involving other ethnic groups are
ongoing (personal communication by authors).
The IMR assays performed to date in Taiwanese
subjects have revealed elevated Ab42 levels,
reduced or no change in Ab40 levels, and
increased tau levels in patients with AD when
compared to normal controls [61, 64–66].
Receiver operating characteristics curve analyses
Table 1 continued
Assay
characteristics
IMRa SIMOAa
Dilution factor
(plasma)
Tau: threefold dilution
Ab42: twofold dilution
Ab40: threefold dilution
Fourfold dilution for all analytes in an automatic
procedure
IMR, Immunomagnetic reduction assay; SIMOA, single molecule array assay; SQUID, superconducting quantum inter-
ference device; ELISA, enzyme-linked immunosorbent assay; T-tau, total tau
a Information in this table was obtained from the websites www.magqu.com and www.quanterix.com, and in the published
studies which used these technologies, as shown in the table
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showed 96% sensitivity and 97% specificity for
distinguishing healthy controls from a hetero-
geneous group of study subjects consisting of
those with mild cognitive impairment (MCI)
due to AD and those with mild to severe AD
(Clinical Dementia Rating scores 0.5–3),
whereas an 80% sensitivity and 82% specificity
was obtained for discriminating patients with
AD from those with MCI [61]. When amyloid
PET imaging was used to stratify the study
subjects, there was 84% sensitivity and 100%
specificity to predict the results of amyloid
detected by PET when the ratio of Ab42 to Ab40
was used [66]. The excellent AD diagnostic
performance indicated by sensitivity and speci-
ficity in these studies using the product of Ab42
and tau has yet to be compared in independent
studies from other sites.
The SIMOA platform has been shown to
detect increases in tau level in patients with AD
from tau levels in patients with MCI and normal
controls, and for Ab and for tau in studies of AD
[36, 39, 56, 67–69]. The results of plasma tau
studies have shown significant increases in tau
in patients with AD, and increases or no chan-
ges in those with MCI compared with normal
controls, while higher plasma tau levels have
also been associated with reduced memory
performance [39, 68]. The authors of these
studies drew the same conclusion that due to
substantial overlap between clinically diag-
nosed groups plasma tau concentration cannot
be used as a prognostic or diagnostic marker.
When plasma Ab42 and Ab40 levels were
assayed by SIMOA, significant decreases were
detected between patients with AD and those
with MCI, between those with AD and subjects
with subjective cognitive decline (SCD), and
between those with AD and normal controls
[36]. The detection levels of plasma Ab1–42
[mean ± standard deviation (SD); normal con-
trols: 19.6 ± 5.2 pg/ml; AD: 13.2 ± 7.3 pg/ml)
were less than 10% of those of plasma Ab1–40
(mean ± SD; normal controls: 276.7 ± 66.1 pg/
ml; AD: 244.3 ± 105.8 pg/ml). In this study, the
CSF Ab levels were not assayed by the SIMOA
assay, but by the Euroimmun immunoassay
(EUROIMMUN AG, Lu¨beck, Germany) [49, 51].
CSF Ab1–42 levels in patients with AD were
significantly decreased compared with other
groups (P\0.0001), while Ab1–40 levels in
patients with AD were only significantly lower
than those of SCD subjects (P = 0.003). The
detected values of CSF Ab42 were
554.0 ± 195.1 pg/ml in normal controls and
289.5 ± 103.8 pg/ml in patients with AD
(P\0.0001), whereas the values of Ab40 were
4688.5 ± 1650.0 pg/ml in normal controls and
4387.2 ± 1761.6 pg/ml in patients with AD (no
statistical significance). Although different
platforms were used to assay CSF and plasma
samples, the results showed that CSF and
plasma Ab42 and Ab40 levels were significantly
positively correlated (Pearson’s correlation
analyses in all participants: r = 0.274, P\0.001
for Ab42; r = 0.136, P = 0.001 for Ab40).
CONCLUSION
Strategies for the development and utility of
blood-based biomarkers for AD have been dis-
cussed in detail recently in several review arti-
cles [30, 70–72]. In this article, we focused on
two new ultra-sensitive immunoaffinity-based
technologies that offer promise for establishing
Ab and tau as blood biomarkers for AD. Cur-
rently, these two platforms are uniquely situ-
ated for further assessment, especially in large
population studies. However, the advance could
be limited by the cost of the instruments, the
lack of high-throughput capacity, and single
suppliers of assay reagents. The availability of a
throughput automated instrument, such as the
SIMOA HD-1 analyzer, will certainly appeal to
pharmaceutical companies when considering
biomarkers to assess the progress of clinical tri-
als in large numbers of subjects, in which
plasma Ab and tau measurements might have
potential utilities. Nevertheless, recent studies
on plasma tau have not confirmed its feasibility
as a diagnostic or prognostic biomarker due to
large overlap between AD and MCI, and
between AD and normal controls, regardless of
the presence of differences in disease-associated
expression. The SIMOA assay for plasma Ab had
shown preliminary potential for utility of diag-
nosis. In these regards, the IMR technology
seems to make more progress, evident from a
series of cohort studies that showed good
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sensitivity and specificity and promising corre-
lations with PET imaging of amyloid and tau.
However, the IMR technology will need to be
assessed vigorously in cohorts of different eth-
nicity, and in longitudinal study of those sub-
jects stratified by amyloid or tau imaging, or by
CSF Ab and tau profiles. Although both plat-
forms are consistent in showing increases in
plasma tau levels in patients with AD, the Ab42
findings were opposite. It has been cautioned
that comparing findings between different
platforms could be problematic [73, 74]. How-
ever, future studies are needed to replicate the
differences in findings between platforms before
the issue of whether plasma Ab42 levels are
increased or decreased in AD can be resolved.
In summary, ultrasensitive platforms are
necessary for establishing whether plasma AD
core markers can be valid blood-based
biomarkers. As pointed out recently by O’Bryant
and colleagues, significant breakthrough in
establishing blood-based biomarkers could be
achieved when the context of use can be
defined at the beginning of biomarker devel-
opment and if approaches from academic
research and industry can be integrated during
the process [71]. Preliminary assessment of
published findings support that both IMR and
SIMOA technologies warrant multicenter
cross-validation study.
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